Galectin Therapeutics (GALT) Given Daily Media Sentiment Rating of -0.03

Media stories about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Galectin Therapeutics earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave news coverage about the company an impact score of 71 out of 100, indicating that recent press coverage is likely to have an impact on the company’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

A number of research firms have recently commented on GALT. Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 26th. HC Wainwright raised Galectin Therapeutics from a “neutral” rating to a “buy” rating and set a $3.50 price objective on the stock in a report on Thursday, March 30th. Finally, FBR & Co reaffirmed a “market perform” rating and set a $2.00 price objective on shares of Galectin Therapeutics in a report on Monday, April 3rd.

Galectin Therapeutics (GALT) remained flat at $2.37 on Wednesday. The company had a trading volume of 56,984 shares. Galectin Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.68. The stock’s 50-day moving average is $2.55 and its 200-day moving average is $1.91. The stock’s market cap is $82.17 million.

Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Monday, May 15th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. On average, equities research analysts expect that Galectin Therapeutics will post ($0.50) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Mideast Time and is the property of of Mideast Time. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.mideasttime.com/galectin-therapeutics-galt-given-daily-media-sentiment-rating-of-0-03/1799424.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GALT”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.